Troxevasin caps. 300mg # 50
Package quantity, pcs:
fifty
one hundred
Category
Diseases of the veins
Scope of the medicinal product
Heart, vessels, blood
Release form
Capsules
Manufacturer country
Bulgaria
Package quantity, pcs
fifty
Release form, composition and packaging
?
Capsules hard gelatinous, size No. 1, cylindrical, yellow
the contents of the capsules are a powder from yellow to yellow-green in color, the presence of conglomerates is allowed, which disintegrate when pressed.
1 caps.
troxerutin 300 mg
lactose monohydrate - 47 mg, magnesium stearate - 3 mg.
Shell composition: quinoline yellow dye (E104) - 0.9%, sunset yellow dye (E110) - 0.039%, titanium dioxide (E171) - 3%, gelatin - up to 100%.
10 pieces.
- blisters (5) - cardboard packs.
10 pieces.
- blisters (10) - cardboard packs.
pharmachologic effect
Angioprotective drug, acts mainly on capillaries and veins.
Reduces the pores between endothelial cells by modifying the fibrous matrix located between endothelial cells.
Inhibits aggregation and increases the degree of deformability of erythrocytes
has an anti-inflammatory effect.
In chronic venous insufficiency, Troxevasin® reduces the severity of edema, pain, seizures, trophic disorders, and varicose ulcers.
Relieves the symptoms associated with hemorrhoids - pain, itching and bleeding.
Due to the beneficial effect on the permeability and resistance of the capillary walls, Troxevasin® helps to slow down the development of diabetic retinopathy.
In addition, its effect on the rheological properties of blood helps to prevent microthrombosis of retinal vessels.
Pharmacokinetics
Absorption After oral administration, absorption is about 10-15%.
Cmax in blood plasma is reached on average 2 hours after administration, therapeutic plasma levels are maintained for 8 hours. Metabolism and excretion Metabolized in the liver.
It is partially excreted unchanged in the urine (20-22%) and in the bile (60-70%).
Indications for use
- chronic venous insufficiency
- postphlebitic syndrome
- trophic disorders in varicose veins
- trophic ulcers
- as an auxiliary treatment after vein sclerotherapy and removal of varicose veins
- hemorrhoids (pain, exudation, itching, bleeding)
- venous insufficiency and hemorrhoids during pregnancy, starting from the second trimester
- as an auxiliary treatment of retinopathy in patients with diabetes mellitus, arterial hypertension and atherosclerosis.
Contraindications for use
- peptic ulcer of the stomach and duodenum in the acute phase
- chronic gastritis in the acute phase
- I trimester of pregnancy
- hypersensitivity to drug components
- hypersensitivity to rutosides.
The drug should be used with caution for a long time in renal failure, as well as in children aged 3 to 15 years.
Dosage regimen
The drug is taken orally during meals.
The capsules should be swallowed whole with plenty of water.
At the beginning of treatment, 300 mg (1 capsule) is prescribed 3 times / day.
The effect usually develops within 2 weeks, after which the treatment is continued at the same dose or reduced to the minimum maintenance dose - 600 mg, or suspended (while the achieved effect persists for at least 4 weeks).
The course of treatment is on average 3-4 weeks, the need for longer treatment is determined individually.
In diabetic retinopathy, it is prescribed at a dose of 0.9-1.8 g / day.
Overdose
Symptoms: agitation, nausea, headache, flushing of the face.
Treatment: gastric lavage, intake of activated charcoal, if necessary - symptomatic therapy.
Side effect
From the digestive system: nausea, diarrhea, heartburn, erosive and ulcerative lesions of the gastrointestinal tract.
Others: skin rash, headache, flushing of the face.
Side effects disappear quickly after stopping treatment.
Drug interactions
The effect of the drug is enhanced by the simultaneous administration of ascorbic acid.
Application for free
Name ENG
TROXEVASIN
Clinical and pharmacological group
A drug used for disorders of venous circulation.
Angioprotector
ATX code
Troxerutin
Dosage
300mg
Structure
1 capsule contains:.
Active ingredient: troxerutin 300 mg
Excipients: lactose monohydrate, magnesium stearate.
Indications
Varicose veins
Chronic venous insufficiency with symptoms such as: swelling and pain in the legs
feeling of heaviness, fullness, tired legs
spider veins and reticules, convulsions, paresthesias
Thrombophlebitis
Periphlebitis
Varicose dermatitis
Pain and swelling of a traumatic nature (with bruises, sprains, injuries).
Contraindications
Hypersensitivity to rutosides or to other components of the drug.
Pregnancy (I trimester).
Peptic ulcer and duodenal ulcer, chronic gastritis in the acute phase.
With caution: should be used (long-term use) in renal failure.
INN / Active ingredient
Troxerutin
Storage conditions and periods
At a temperature not higher than 25 degrees.
Expiration date: 5 years
Specifications
Category
Diseases of the veins
Scope of the medicinal product
Heart, vessels, blood
Release form
Capsules
Manufacturer country
Bulgaria
Package quantity, pcs
fifty
Way of introduction
Through the mouth
Vacation conditions
Without recipe
Brand name
Troxevasin
The amount of the dosage form in the primary package
10 pieces.
Primary packaging type
Blister
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Venotonic and venoprotective agent
Anatomical and therapeutic characteristics
C05CA04 Troxerutin
Dosage form
Capsules
Dosage (volume) of the substance in the preparation
troxerutin 300 mg
Expiration date in days
1826
Package weight, g
40
Mode of application
:
Inside, at the beginning of treatment, 1 capsule is prescribed 2 times a day (morning and evening), during maintenance therapy - 1 capsule per day for 3-4 weeks or more. < br> With retinopathy, the drug is prescribed 1-2 capsules 3 times a day. < br> Capsules should be taken with meals.
Information on technical characteristics, delivery set, country of manufacture